Anti-osteoporosis Medication Monitoring and Management Service

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BACKGROUND:

One-year adherence to oral anti-osteoporosis medication (AOMs) was only about 30%. In recent years, efforts have been made to change the delivery of these medications from oral form to injection form every, 3, 6 or 12 months to increase adherence. However, both patients and providers are sometimes confused about the multiple choices. Also, patients may receive extra medications if providers did not keep tract of their previous AOM uses or patients may changes providers. There were urgent needs to provide AOM monitoring and management services to improve cares.

OBJECTIVES:

To establish a anti-osteoporosis medication management service at National Taiwan University Hospital and its BeiHu Branch.

METHODS:

Participating physicians will select those eligible for services and refer to study coordinators. Study coordinators will conduct baseline assessments on osteoporosis/fracture risks, record medical conditions, AOMs, provide educations on osteoporosis, fracture, sarcopenia, fall, medications, nutrition, and exercise. They also arrange return clinic visit, telephone reminder and follow up for patients, and communicate with providers on regular bases. the investigators plan to enroll 500 patients with 18-month follow up for each.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration

NCT06024148

Osteoporosis Fracture

UNKNOWN

The Optimal Long Term Treatment Strategy of Anti-resorptive Medications

NCT05091086

Osteoporosis Bone Mineral Density

ACTIVE_NOT_RECRUITING PHASE4

Osteoporosis Treatment in Post-menopausal Women

NCT03006003

Depressive Syndrome

UNKNOWN PHASE4

Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

NCT07283887

Osteoporosis

RECRUITING PHASE4

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

NCT06938152

Osteoporosis Osteoporosis Postmenopausal

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis Fracture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>=50 and one of the below
* Newly prescribed with AOMs
* Recent change of AOMs
* Poor adherence to AOMs
* Participating physicians feel that the service will benefit the patient in overall osteoporosis and medication managements.

Exclusion Criteria

* Life expectancy less than 2 years or can't be assessed for communication problems
* patient in our fracture liaison service or other medication clinical trials

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No